Docstoc

Topic

Document Sample
Topic Powered By Docstoc
					Topic                           Work        Published/   Date of       Referral    Date of final Start of
                                programme   ongoing      marketing     date (2)    NICE          NICE
                                                                                                             (3)
                                                         authorisation             guidance      appraisal
                                                         (1)


Xolair (omalizumab) for         8           Published    October       April 2003 November       November
uncontrolled asthma                                      2005                     2007           2006
Remicade (infliximab) for       8           Published    September     April 2003 January        March 2007
psoriasis                                                2005                     2008
Natrecor (nesiritide) for heart 9           Ongoing      n/a           October     n/a           October
failure (acute                                                         2003                      2003
decompensated)
Erbitux (cetuximab) for head 10             Published    March 2006    June 2004 June 2008       June 2006
and neck cancer
Iressa (gefitinib) for lung     10          Ongoing      n/a           June 2004 n/a             January
cancer (non-small cell) - 2nd                                                                    2009
Line Use
Iressa (gefitinib) for non      10          Ongoing      Expected      June 2004 n/a             June 09
small cell lung cancer (1st                              October
line use)                                                2009
Tysabri (natalizumab) for       10          Published    June 2006     June 2004 August 2007 September
multiple sclerosis                                                                           2006
Alimta (pemetrexed) for         10          Published    September     June 2004 January         April 2005
mesothelioma                                             2004                    2008
Erbitux (cetuximab) for head 10             Published    March 2006    June 2004 June 2008       June 2006
and neck cancer
Campto (irinotecan) for colon 10            Ongoing      n/a           June 2004 n/a             n/a
cancer (adjuvant)
Mabthera (rituximab) for        11          Published    August 2004 April 2005 February         April 2007
untreated stage III or IV                                                       2008
follicular lymphoma(4)
Taxol (paclitaxel) for early    11          Published    March 2005    April 2005 September      November
node-positive breast cancer                                                       2006           2005
Taxotere (docetaxel) for        11          Published    March 2006    April 2005 September      November
early node-positive breast                                                        2006           2005
cancer
Gemzar (gemcitabine) for        11          Published    September     April 2005 January        February
metastatic breast cancer                                 2004                     2007           2006
Fludara (fludarabine) for       11          Published    February      April 2005 February       February
chronic lymphocytic                                      2003                     2007           2006
leukaemia
Alimta (pemetrexed) for the     11          Published    September     April 2005 August 2007 April 2006
treatment of non-small cell                              2004
lung cancer
Tarceva (erlotinib) for lung    11          Published    September     April 2005 November       March 2006
cancer (non-small cell)                                  2005                     2008
Idraparinux sodium for          12          Ongoing      n/a           July 2006   n/a           July 2006
stroke (in patients with atrial
fibrillation)
Arava (leflunomide) for         12          Ongoing      June 2004     July 2006   n/a           July 2006
psoriatic arthritis (moderate
to severe)
Idraparinux sodium for           12   Ongoing     n/a          July 2006   n/a          July 2006
venous thromboembolism
(recurrent)
Herceptin (trastuzumab) for      12   Published   May 2006     July 2005   August 2006 December
early-stage HER2-positive                                                              2005
breast cancer
Alteplase (actilyse) for the 12       Published   June 2002    July 2006   June 2007    September
treatment of acute ischaemic                                                            2006
stroke
Champix (varenicline) for        12   Published   September    July 2006   July 2007    November
smoking cessation                                 2006                                  2006
Humira (adalimumab) for the 12        Published   August 2005 July 2005    August 2007 September
treatment of psoriatic                                                                 2006
arthritis
MabThera (rituximab) for the 12       Published   July 2006    July 2005   August 2007 September
treatment of rheumatoid                                                                2006
arthritis
Velcade (bortezomib) for         12   Published   April 2004   July 2005   October      December
multiple myeloma                                                           2007         2005
Orencia (abatacept) for          12   Published   May 2007     July 2006   April 2008   October
rheumatoid arthritis                                                                    2006
Tyverb (lapatinib) for breast    13   Ongoing     June 2008    December n/a             February
cancer (advanced or                                            2006                     2007
metastatic)
Cimzia (certolizumab) for        13   Ongoing     n/a          December n/a             December
rheumatoid arthritis                                           2006                     2006
Remicade (infliximab) for        13   Published   February     December December        March 2007
ulcerative colitis (acute                         2006         2006     2008
exacerbations)
Remicade (infliximab) for        13   Published   February     December April 2008      March 2007
ulcerative colitis                                2006         2006
Acomplia (rimonabant) for        13   Published   June 2006    December June 2008       June 2007
obesity                                                        2006
Baraclude (entecavir) for        14   Published   June 2006    June 2007 August 2008 September
Hepatitis B                                                                          2007
Sebivo (telbivudine) for         14   Published   April 2007   June 2007 August 2008 September
Hepatitis B                                                                          2007
Adenuric (febuxostat) for        14   Published   April 2008   June 2007 December       August 2007
hyperuricaemia                                                           2008
Humira (adalimumab) for the 14        Published   December     June 2007 June 2008      July 2007
chronic psoriasis                                 2007
Ixabepilone for breast cancer 15      Ongoing     n/a          December n/a             July 2008
(locally advanced or                                           2007
metastatic)
Erbitux (cetuximab) for          15   Ongoing     July 2008    December n/a             January
colorectal cancer (first line)                                 2007                     2008
Erbitux (cetuximab) for lung     15   Ongoing     n/a          December n/a             October
cancer (non-small cell)                                        2007                     2008
Revlimid (lenalidomide) for     15   Ongoing     June 2007    December n/a           April 2008
multiple myeloma                                              2007
Xeloda (capectitabine) for      15   Ongoing     n/a          December n/a           June 2009
pancreatic cancer                                             2007
Pradaxa (dabigatran) for        15   Published   March 2008   December September     January
venous thromboembolism                                        2007     2008          2008
Erbitux (cetuximab) for head 16      Ongoing     March 2006   March       n/a        March 2008
and neck cancer (squamous                                     2008
cell carcinoma)
Effient (prasugrel) for acute   17   Ongoing     n/a          June 2008 n/a          November
coronary artery syndrome                                                             2008
Viread (tenofovir disoproxil    17   Ongoing     April 2008   June 2008 n/a          August 2008
fumarate) for Hepatitis B
Nexavar (sorafenib) for         17   Ongoing     October      June 2008 n/a          August 2008
hepatocellular carcinoma                         2007
(advanced and metastatic)
Orencia (abatacept) for         17   Ongoing     May 2007     June 2008 n/a          January
juvenile idiopathic arthritis                                                        2009
Humira (adalimumab) for         17   Ongoing     n/a          June 2008 n/a          September
juvenile idiopathic arthritis                                                        2008
Sprycel (dasatinib) for         17   Ongoing     November     June 2008 n/a          July 2008
leukaemia (acute                                 2006
lymphoblastic)
Temodal (temoazolomide)    17        Ongoing     June 2005    June 2008 n/a          March 2009
for melanoma (advanced and
metastatic
Mifamurtide for                 17   Ongoing     n/a          June 2008 n/a          August 2008
osteosarcoma
Romiplostim for                 17   Ongoing     n/a          June 2008 n/a          August 2008
thrombocytompenic pupura
Promacta (eltrombopag) for      17   Ongoing     n/a          June 2008 n/a          March 2009
thrombocytopenic purpura
Xarelto (rivaroxaban) for       17   Published   July 2008    June 2008 April 2009   August 2008
venous thromboembolism
Azacitidine for acute       18       Ongoing     n/a          July 2008   n/a        January
myelomonocytic leukaemia                                                             2009
and acute myeloid leukaemia
Xeloda (capecitabine) for       18   Ongoing     January      July 2008   n/a        December
advanced gastric cancer                          2008                                2008
Relistor (methylnaltrexone)     18   Ongoing     July 2008    July 2008   n/a        February
for opioid-induced                                                                   2009
constipation in patients
receiving palliative care
Datiros (alitretinoin) for 18        Ongoing     n/a          July 2008   n/a        October
severe chronic hand eczema                                                           2008
Alimta (pemetrexed) for         18   Ongoing     April 2008   July 2008   n/a        June 2009
locally advanced or
metastatic non-small cell
lung cancer
Mabthera (rituximab) for        18   Ongoing     n/a          July 2008   n/a        September
relapsed treatment of                                                          2009
chronic lymphocytic
leukaemia
Mabthera (rituximab) for          18   Ongoing   n/a         July 2008   n/a   September
chronic lymphocytic                                                            2008
leukaemia (first line)
Sutent (sunitinib) for            18   Ongoing   July 2006   July 2008   n/a   August 2008
gastrointestinal stromal
tumours
Actemra (tocillizumab) for        18   Ongoing   n/a         July 2008   n/a   November
rheumatoid arthritis                                                           2008
Hycamtin (topotecan) for          18   Ongoing   n/a         July 2008   n/a   December
carcinoma of the cervix                                                        2008
Yondelis (trabectedin) for        18   Ongoing   September   July 2008   n/a   September
advanced metastatic soft                         2007                          2008
tissue sarcoma
Ustekinumab for moderate to 18         Ongoing   n/a         July 2008   n/a   November
severe psoriasis                                                               2008
Golimumab for rheumatoid          19   Ongoing   n/a         Nov 2008    n/a   To be
arthritis (after failure of                                                    confirmed
previous antirheumatic
drugs) -
Golimumab for rheumatoid          19   Ongoing   n/a         Nov 2008    n/a   To be
arthritis (methotrexate-                                                       confirmed
naïve)
Golimumab for ankylosing          19   Ongoing   n/a         Nov 2008    n/a   To be
spondylitis -                                                                  confirmed
Golimumab for psoriatic           19   Ongoing   n/a         Nov 2008    n/a   To be
arthritis                                                                      confirmed
Bevacizumab in combination 19          Ongoing   January     Nov 2008    n/a   May 2009
with oxaliplatin and either                      2008
5FU or capecitabine for
colorectal cancer
(metastatic)
Dronedarone for atrial            19   Ongoing   n/a         Nov 2008    n/a   June 09
fibrillation and atrial flutter
Erlotinib (in combination with 19      Ongoing   n/a         Nov 2008    n/a   To be
bevacizumab) for non small                                                     confirmed
cell lung cancer (advanced or
metastatic maintenance
treatment)
Erlotinib (monotherapy) for       19   Ongoing   n/a         Nov 2008    n/a   September
non small cell lung cancer                                                     2009
(advanced or metastatic
maintenance treatment)
Bevacizumab, in combination 19         Ongoing   n/a         Nov 2008    n/a   October
with non-taxane                                                                2009
chemotherapy for breast
cancer (first line)
Temsirolimus for mantle cell      19   Ongoing   n/a         Nov 2008    n/a   November
lymphoma (relapsed)                                                            2009
Trabectedin for ovarian        19   Ongoing   n/a          Nov 2008    n/a   November
cancer (relapsed)                                                            2009
Vandetanib for non small       19   Ongoing   Received      Nov 2008   n/a   December
cell lung cancer (second line)                marketing                      2009
                                              authorisation
                                              for stage
                                              IIIB and IV
                                              NSCLC in
                                              early 2010.
Erlotinib (in combination with 19   Ongoing   n/a          Nov 2008    n/a   To be
bevacizumab) for non small                                                   confirmed
cell lung cancer (advanced or
metastatic second line)
Sunitinib malate (in           19   Ongoing   n/a          March       n/a   January
combination with                                           2009              2010
capecitabine) for breast
cancer (advanced and/or
metastatic)
Sunitinib malate (in           19   Ongoing   n/a          March       n/a   January
combination with a taxane)                                 2009              2010
for advanced and/or
metastatic breast cancer
(first line treatment)
Trastuzumab (Herceptin) for 19      Ongoing   n/a          March       n/a   November
HER-2 positive advanced                                    2009              2010
gastric cancer
Rituximab for follicular non   19   Ongoing   n/a          March       n/a   August 2010
Hodgkins lymphoma                                          2009
(maintenance treatment
following response to first-
line chemo)
Liraglutide for diabetes       20   Ongoing   n/a          May 2009    n/a   August 2009
mellitus (type 2) -
Denosumab (AMG-162) for        20   Ongoing   n/a          April 2009 n/a    November
osteoporotic fractures in                                                    2009
post-menopausal women
(prevention)
Cladribine for multiple        20   Ongoing   n/a          April 2009 n/a    November
sclerosis                                                                    2009
(relapsing/remitting)
Ticagrelor (AZD6140) for       20   Ongoing   n/a          April 2009 n/a    March 2010
acute coronary syndromes
Fingolimod for multiple        20   Ongoing   n/a          April 2009 n/a    May 2010
sclerosis
(relapsing/remitting)
Fingolimod for multiple        20   Ongoing   n/a          April 2009 n/a    To be
sclerosis (primary                                                           confirmed
progressive)
ABT-874 for chronic plaque     20   Ongoing   n/a          April 2009 n/a    March 2011
psoriasis (moderate-to-
severe)
Everolimus for renal cell      20   Ongoing   n/a          November n/a      July 2009
carcinoma (advanced and/or                                                                2008
metastatic) - 2nd line
Pazopanib for renal cell             20               Ongoing           n/a               November n/a                    February
cancer (1st line advanced                                                                 2008                            2010
and/or metastatic)
Pazopanib for renal cell             20               Ongoing           n/a               November n/a                    March 2010
cancer (2nd line advanced                                                                 2008
and/or metastatic)
Pemetrexed for non small             20               Ongoing           n/a               November n/a                    June 2009
cell lung cancer                                                                          2008
(maintenance)
Ipilimumab for melanoma       20                      Ongoing           n/a               November n/a                    August 2010
(previously treated                                                                       2008
unresectable stage III or IV)
Ipilimumab in combination    20                       Ongoing           n/a               November n/a                    August 2010
with dacarbazine for                                                                      2008
melanoma (previously
untreated unresectable stage
III or IV)
Dutasteride for prostate             20               Ongoing           n/a               March          n/a              November
cancer                                                                                    2009                            2009
Contusugene ladenovec for            20               Ongoing           n/a               March          n/a              March 2010
head and Neck cancer                                                                      2009
Panitumumab (in              20                       Ongoing           n/a               March          n/a              June 2010
combination with                                                                          2009
chemotherapy) for colorectal
cancer (metastatic)
Nilotinib for chronic myeloid 20                      Ongoing           n/a               March          n/a              August 2010
leukaemia                                                                                 2009
Imatinib for gastrointestinal        21               Ongoing           May 2009          April 2009 n/a                  September
stromal tumours (GIST) -                                                                                                  2009
adjuvant
Bevacizumab for                      21               Ongoing           n/a               April 2009 n/a                  November
glioblastoma multiforme                                                                                                   2009
(relapsed)
Denosumab for therapy-               21               Ongoing           n/a               April 2009 n/a                  September
induced bone loss in non-                                                                                                 2009
metastatic breast cancer
Denosumab for therapy-               21               Ongoing           n/a               April 2009 n/a                  December
induced bone loss in non-                                                                                                 2009
metastatic prostate cancer
(1)
    Date of marketing authorisation by European Medicines Agency (EMEA).
(2)
    Topics before the 13th work programme were originally referred to NICE’s Multiple Technology Appraisal (MTA) programme and were
transferred to the STA programme when it was introduced in August 2006. The date provided is the date the topic was originally referred to
NICE as a Multiple Technology Appraisal.
(3)
    The date NICE commenced work on the appraisal. NICE will also have carried out scoping work for the appraisal before this date.
(4)
    Guidance has been reviewed since the original guidance was published. The date of final guidance and date NICE started work on the
appraisal refer to the review.

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:13
posted:2/24/2010
language:English
pages:7